Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Bio-Techne Lands Government Contract for Genomic Prostate Cancer Test

Bio-Techne Lands Government Contract for Genomic Prostate Cancer Test

Mar 18, 2020
|
staff reporter

NEW YORK – Bio-Techne on Wednesday said that the General Services Administration (GSA) has awarded a 10-year reimbursement contract to its Exosome Diagnostics laboratory for the ExoDx Prostate (EPI) test.

The contract took effect today, providing 9 million additional men access to the urine-based genomic EPI test for early detection of prostate cancer, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Keep It (Partly) Virtual

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

For Cross-Protection

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Proteomics of Severity

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

Genome Biology Papers on Regulatory Element, Single-Cell Integration, Sequence Simulation Tools

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.

What's Popular?

In Business News

  1. Olink Files For Public Offering in US

  2. Twist Bioscience, Watchmaker Genomics Partner on High-Throughput NGS Applications

  3. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M

  4. Quanterix Q4 Revenues Up 64 Percent

  5. Quidel Stock Plunges in February as GenomeWeb Index Falls 3 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.